Immunologic enhancement with intermittent interleukin-2 therapy
Patent 5696079 Issued on December 9, 1997. Estimated Expiration Date: 
May 26, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
May 26, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesImmunotherapy for AIDS patients Dipeptidyl 2-amino-1,2-dideoxy-D-glucose derivatives as host resistance enhancers in AIDS-immunocompromised hosts and methods of use Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds Immunologic enhancement with intermittent interleukin-2 therapy Patent #: 5419900 InventorsAssigneeApplicationNo. 452440 filed on 05/26/1995US Classes:514/2, Peptide containing (e.g., protein, peptones, fibrinogen, etc.) DOAI424/85.4, Interferon424/85.5, Gamma or immune435/7.1, Involving antigen-antibody binding, specific binding protein assay or specific ligand-receptor binding assay435/69.1, Recombinant DNA technique included in method of making a protein or polypeptide435/252.3, Transformants (e.g., recombinant DNA or vector or foreign or exogenous gene containing, fused bacteria, etc.)435/320.1, VECTOR, PER SE (E.G., PLASMID, HYBRID PLASMID, COSMID, VIRAL VECTOR, BACTERIOPHAGE VECTOR, ETC.) BACTERIOPHAGE VECTOR, ETC.)514/44, Polynucleotide (e.g., RNA, DNA, etc.)530/350, PROTEINS, I.E., MORE THAN 100 AMINO ACID RESIDUES536/23.1, DNA or RNA fragments or modified forms thereof (e.g., genes, etc.)536/23.5Encodes an animal polypeptideExaminersPrimary: Ulm, JohnAssistant: Sorensen, Kenneth A. Attorney, Agent or FirmForeign Patent References
International ClassA61K 038/20Foreign Application Priority Data1994-05-19 WOAbstractA method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy. By this approach the cells are first activated in vivo via the aforementioned IL-2 therapy, and transduction then is effected by delivering a genetically engineered retrovital vector directly to the patient.Other References
Field of SearchInvolving antigen-antibody binding, specific binding protein assay or specific ligand-receptor binding assayRecombinant DNA technique included in method of making a protein or polypeptide Transformants (e.g., recombinant DNA or vector or foreign or exogenous gene containing, fused bacteria, etc.) VECTOR, PER SE (E.G., PLASMID, HYBRID PLASMID, COSMID, VIRAL VECTOR, BACTERIOPHAGE VECTOR, ETC.) BACTERIOPHAGE VECTOR, ETC.) DNA or RNA fragments or modified forms thereof (e.g., genes, etc.) Encodes an animal polypeptide PROTEINS, I.E., MORE THAN 100 AMINO ACID RESIDUES Polynucleotide (e.g., RNA, DNA, etc.) Peptide containing (e.g., protein, peptones, fibrinogen, etc.) DOAI Interferon Gamma or immune |
| ||||||||||||||
